Floatz logo

Wu-Cart-007

Lymphoblastic Lymphoma

Wugen, Inc.Cell therapyPhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

83 Active assets in the Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Washington
Phase 4BBB
Cladribine
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 4BBB
ASPARAGINASE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB
MERCAPTOPURINE ANHYDROUS
City of Hope Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Wu-Cart-007 is also rated in:

T-cell acute lymphoblastic leukemiaDormant
B
Indicative ·
58 / 100
View asset →
T-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
enteropathy-associated T-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →